Latest Loan Facilities News

Credit Clear Limited has outperformed its FY25 financial guidance with a 76% rise in underlying EBITDA and secured exclusive digital debt recovery contracts with leading insurers, setting a robust stage for FY26 growth.

Ballard Mining has launched a comprehensive 130,000-metre drilling campaign at its Mt Ida Gold Project, targeting resource expansion and development of the Baldock deposit. Supported by a recent oversubscribed $30 million IPO, the program aims to unlock new exploration targets along a 26km strike in Western Australia’s Goldfields region.

Sheffield Resources reported record quarterly production and positive operating cashflow at its Thunderbird Mine, while progressing its South Atlantic Project in Brazil with a maiden resource estimate and key approvals.

International Equities Corporation Ltd has revealed a significant revenue drop and net loss for Q2 2025, citing economic slowdown and weak tourism as key challenges. The company signals cautious optimism for the hospitality sector despite ongoing cost pressures.

Aeris Resources reported a robust June 2025 quarter with increased copper and gold production, improved cost efficiencies, and successful refinancing, while advancing exploration at key projects.

Renegade Exploration Limited has announced a $2.29 million placement to fund exploration across its Yukon, Nevada, and Cloncurry projects, alongside partial loan repayment and operational costs.

Norwood Systems delivered its strongest quarter yet with record cash inflows, significant debt reduction, and expanding global partnerships, setting a robust foundation for FY2026.

Lumos Diagnostics reported a 12% revenue increase for FY25 and inked a landmark US$317 million exclusive distribution deal for its FebriDx test, while advancing its FDA CLIA waiver application.

Truscott Mining Corporation has re-established gold production in the Tennant Creek gold field and is progressing the Westminster high-grade gold project through advanced geological research and a structured development plan.

Mesoblast has reported a strong commercial debut for Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, generating US$13.2 million in gross revenue in its initial quarter. The company is advancing regulatory and clinical milestones while expanding insurance coverage across the US.

Lumos Diagnostics has locked in a A$5 million secured loan facility to support working capital as it advances toward FDA CLIA waiver for its FebriDx® test, complementing a landmark US distribution deal.

New World Resources has unanimously recommended Central Asia Metals’ improved takeover bid, which offers a higher price and unconditional terms, setting the stage for a decisive shareholder vote.